Aladdin Healthcare Technologies SE

  • WKN: A12ULL
  • ISIN: DE000A12ULL2
  • Land: Deutschland

Nachricht vom 24.02.2021 | 07:59

Aladdin Healthcare Technologies jointly develops AI-Platform for Cardiovascular Diseases that achieves three Patents in China

DGAP-News: Aladdin Healthcare Technologies SE / Key word(s): Patent/Miscellaneous
24.02.2021 / 07:59
The issuer is solely responsible for the content of this announcement.

Aladdin Healthcare Technologies jointly develops AI-Platform for Cardiovascular Diseases that achieves three Patents in China

- Aladdin has developed patented AI-platform together with its partner IIAT in China

- The innovative AI-driven platform marks a turning point in the early diagnostics of heart diseases

- Next step is gaining patent approval also in the USA and Europe

BERLIN/LONDON February 24, 2021 - Aladdin Healthcare Technologies SE ("Aladdin", ISIN: DE000A12ULL2), a leading developer of Artificial Intelligence (AI) based healthcare diagnostics and drug discovery applications, has developed together with its partner IIAT (Imperial Institute of Advanced Technology) an innovative AI-powered data analysis platform for cardiovascular diseases. The platform has just successfully gained three patents in China.

Aladdin achieves a milestone in the early diagnostics of cardiovascular diseases. By combining multimodal data specifically integrated AI-driven blood analysis, the Company brings a novel approach of early diagnostics to market. Moreover, most other currently available AI approaches reflect the reliance of the industry on utilising cardiac images as a singular approach methodology. This is only adequate for basic diagnosis and does not approach the multiple complexities that involve the disease and its underlying pathways.

The AI-data platform has gained three patents in China that include:
a. Automated Multimodal Cardiac Image Analysis, Visualisation and 3D Printing
b. Multiscale Auto-focused Super-resolution
c. High-resolution Myocardial Motion Analysis System

The IIAT has been established by a team of royal academicians and professors from Imperial College London and Royal Brompton Hospital. It is a new research and development institute engaging the international exchange and cooperation in science and technology, Chinese-European technology transfer, and research in medical imaging technology. It is also committed to bringing human resources, technologies as well as projects in the field of healthcare from Europe to China and promoting them in China.

Wade Menpes-Smith, CEO of Aladdin Healthcare Technologies, comments: "The achievement of three patents in China is a further acknowledgment of our ability in improving the world of healthcare diagnostics with our expertise and together with our important network of international partners." Under the agreement with IIAT, Aladdin has all international rights to license the AI-technology in Europe, UK and the USA, but not in China. The Company is planning to seek patent approval in the USA and Europe as next step.

As part of the new international growth strategy, Aladdin will list its shares on the OTC market in the USA.

About Aladdin Healthcare Technologies SE
Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin Healthcare Technologies Ltd.) is a leading developer of AI healthcare diagnostics and drug discovery applications that can accelerate both early stage disease diagnosis and the end-to-end drug discovery process. Aladdin targets age-related diseases including a significant focus on Alzheimer's disease. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to confidentially and securely gather targeted data including genome, tabular, MRI, PET, cognition and other lifestyle data. These datasets are then analysed by our award-winning AI team and used to develop proprietary AI tools that can assist healthcare professionals to more accurately and efficiently diagnose age-related diseases. This new diagnostic process will save significant time and costs for healthcare professionals. Additionally, our AI drug discovery platform will be used by pharmaceutical Companies to speed up drug development, clinical trials and predict outcomes more accurately.

Website Link:

For further information:

Aladdin Healthcare Technologies Ltd.
24-26 Baltic Street West
London EC1Y 0UR
Phone +44 7714 719696

Contact Press
CROSS ALLIANCE communication GmbH
Sara Pinto
Phone +49 89 1250 90330

24.02.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

Event im Fokus

Termine 2021

10. Juni 2021:Fachkonferenz Immobilien

14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure

13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie

10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix

„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“


Cryptology Asset Group PLC: 120 % Kurspotenzial

GBC Research hat mit der Coverage der Cryptology Asset Group PLC (ISIN: MT0001770107) begonnen. Die Bewertung der führenden europäischen Investmentgesellschaft für Krypto-Assets und Blockchain-Unternehmen erfolgte mittels der Berechnung des Net Asset Value (NAV). Unter Berücksichtigung aller Beteiligungen ergibt sich zum 05. Juli 2021 eine GBC-Fair-NAV-Bewertung in Höhe von 1,04 Mrd. EUR. Daraus ergibt sich ein NAV je Cryptology-Aktie von 358,43 EUR. Daher empfiehlt GBC Research die Cryptology-Aktie zum Kauf und sieht ein Kurspotenzial von über 120 %.

News im Fokus

Vonovia SE: Takeover offer for Deutsche Wohnen - minimum shareholder approval of 50% not expected to be reached (news with additional features)

23. Juli 2021, 17:41

Aktueller Webcast


H1 2021 Analyst Call

04. August 2021

Aktuelle Research-Studie

Original-Research: Diversified Energy PLC (von First Berlin Equity Research GmbH): Kaufen Diversified Energy PLC

23. Juli 2021